Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Corporate Profile

igeneon AG

Vienna, Austria

Technology: Cancer immunotherapies

Disease focus: Epithelial

Read the full 71 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE